

antiviral and associated therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
ivermectin	15 studies ¹	0.72 [0.32 ; 1.61], 3 RCTs, I2=76% inconclusive result	1.72 [1.02 ; 2.88], 2 RCTs, I2=0% moderate degree of certainty	0.37 [0.16 ; 0.86], 6 RCTs, I2=0% moderate degree of certainty	0.93 [0.78 ; 1.10], 2 RCTs, I2=0% inconclusive result
favipiravir	10 studies ²	-	1.66 [1.28 ; 2.15], 4 RCTs, I2=0% moderate degree of certainty	1.13 [0.75 ; 1.70], 6 RCTs, I2=0% inconclusive result	1.54 [0.97 ; 2.42], 6 RCTs, I2=72% inconclusive result
chloroquine and derivatives	8 studies ³	0.98 [0.72 ; 1.34], 4 RCTs, I2=0% inconclusive result	1.01 [0.59 ; 1.74], 1 RCT, I2=0% inconclusive result	1.08 [0.63 ; 1.87], 7 RCTs, I2=0% inconclusive result	0.83 [0.57 ; 1.21], 2 RCTs, I2=0% inconclusive result
azithromycin	3 studies ⁴	-	0.82 [0.47 ; 1.43], 1 RCT, I2=0% inconclusive result	0.43 [0.13 ; 1.44], 1 RCT, I2=0% inconclusive result	715.00 [12.94 ; 39513.71], 1 study, I2=0% certainty unassessable
nitazoxanide	3 studies ⁵	1.02 [0.29 ; 3.58], 1 RCT, I2=0% inconclusive result	0.81 [0.52 ; 1.27], 1 RCT, I2=0% inconclusive result	1.02 [0.02 ; 51.70], 1 RCT, I2=0% inconclusive result	-
remdesivir	3 studies ⁶	-	1.12 [0.72 ; 1.75], 3 RCTs, I2=79% demonstrated inconclusive result	0.70 [0.39 ; 1.26], 3 RCTs, I2=0% inconclusive result	-
umifenovir (arbidol)	2 studies ⁷	0.86 [0.06 ; 11.36], 1 RCT, I2=0% inconclusive result	-	-	2.80 [0.31 ; 25.53], 1 RCT, I2=0% inconclusive result
azvudine	1 study ⁸	-	-	1.00 [0.02 ; 55.80], 1 RCT, I2=0% inconclusive result	28.50 [1.27 ; 640.66], 1 RCT, I2=0% certainty unassessable
bromhexine	1 study ⁹	0.48 [0.01 ; 27.44], 1 RCT, I2=0% inconclusive result	-	-	-
doxycycline	1 study ¹⁰	0.44 [0.23 ; 0.84], 1 RCT, I2=0% certainty unassessable	1.89 [1.06 ; 3.38], 1 RCT, I2=0% certainty unassessable	0.16 [0.01 ; 3.25], 1 RCT, I2=0% inconclusive result	-

Continued on next page

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
Ensitrelvir (XOCOVA)	1 study ¹¹	-	-	-	-
favipiravir plus interferon	1 study ¹²	-	-	0.83 [0.23 ; 2.96], 1 RCT, I2=0% inconclusive result	-
hydroxychloroquine plus macrolides	1 study ¹³	0.99 [0.57 ; 1.72], 1 RCT, I2=0% inconclusive result	0.81 [0.54 ; 1.22], 1 RCT, I2=0% inconclusive result	0.64 [0.18 ; 2.24], 1 RCT, I2=0% inconclusive result	-
lopinavir/ritonavir	1 study ¹⁴	3.69 [0.37 ; 36.57], 1 RCT, I2=0% inconclusive result	3.92 [1.66 ; 9.24], 1 RCT, I2=0% certainty unassessable	1.20 [0.65 ; 2.19], 2 RCTs, I2=0% inconclusive result	3.24 [1.15 ; 9.10], 2 RCTs, I2=24% demonstrated moderate degree of certainty
lopinavir/ritonavir, ribavirin and interferon beta-1b	1 study ¹⁵	-	3.92 [1.66 ; 9.24], 1 RCT, I2=0% certainty unassessable	0.47 [0.01 ; 24.30], 1 RCT, I2=0% inconclusive result	4.37 [1.86 ; 10.25], 1 RCT, I2=0% demonstrated certainty unassessable
sofosbuvir and ledipasvir	1 study ¹⁶	-	-	-	-

Notes

¹I-TECH (Lim), 2022 (NCT04920942); Abd-Elsalam, 2021 (NCT04403555); Babalola, 2021 (); Bukhari, 2021 (NCT04392713); Kirti, 2021 (CTRI/2020/08/027225); RIVET-COV (Mohan) (12mg and 24mg), 2021 (CTRI/2020/06/026001); Ahmed, 2020 (); Chaccour, 2020 (NCT04390022); Chachar, 2020 (NCT04739410); Krolewiecki, 2020 (NCT004381884); NCT04523831 (Mahmud), 2020 (NCT04523831); Shahbaznejad, 2020 (IRCT20111224008507N3); Glorial F, 2020 (NCT04343092); Espitia-Hernandez, 2020 (); Spoorthi, 2020 ()

²FACCT Trial, 2021 (NCT04392973); Holubar M, 2021 (NCT04346628); Shenoy S, 2021 (NCT04529499); Shinkai, 2021 (JapicCTI-205238); Solaymani-Dodaran, 2021 (IRCT20200318046812N1); AVI-FAVIR, 2020 (NCT04434248); Dabbous HM, 2020 (NCT04349241); NCT04542694, 2020 (NCT04542694); Ruzhentsova T, 2020 (NCT04501783); Udwadia, 2020 (CTRI/2020/05/025114)

³FACCT Trial, 2021 (NCT04392973); Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 (NCT04322123); HC-nCoV (Shanghai), 2020 (NCT04261517); Kamran, 2020 (NCT04491994); NCT04333654, 2020 (NCT04333654); NCT04342650, 2020 (NCT04342650); Zhaowei Chen, 2020 (ChiCTR2000029559); Min, 2020 ()

⁴Rashad A (AZI vs SoC), 2021 (); COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (NCT04322123); Espitia-Hernandez, 2020 ()

⁵Fontanesi, 2021 (NCT04348409); Silva, 2021 (NCT04463264); Rocco, 2020 (NCT04552483)

⁶GS-US-540-5773 (Goldman), 2020 (NCT04292899); GS-US-540-5774, 10 days, 2020 (NCT04292730); GS-US-540-5774, 5 days, 2020 (NCT04292730)

⁷ELACOI (Lopinavir/ritonavir), 2020 (NCT04252885); Yethindra, 2020 (None)

⁸Ren, 2020 (ChiCTR2000029853)

⁹Li T, 2020 (NCT04273763)

¹⁰Spoorthi, 2020 ()

¹¹Mukae - Phase 2a, 2022 (jRCT2031210350)

¹²Khamis, 2020 ()

¹³Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 (NCT04322123)

¹⁴ELACOI (lopinavir/ritonavir), 2020 (NCT04252885)

¹⁵Hung et al., 2020 (NCT04276688)

¹⁶Nourian A, 2020 (IRCT20100228003449)